Bryan Johnson’s Peptide Stack, Fact-Checked: What the Evidence Actually Says

Bryan Johnson rubs eight different growth-factor peptides into his scalp, swallows up to thirty grams of collagen a day,¹ and once paired an approved drug with a growth-hormone secretagogue on the hunch that their side effects might cancel each other out. What makes the Blueprint protocol worth reading is not the length of the list — it is that Johnson runs it through a biomarker panel and quits the things that fail.¹

Blueprint is, by Johnson’s own framing, a protocol that “is constantly evolving.” That caveat matters here, because a fact-check of a moving target can only describe a snapshot — mid-2025, in this case. What follows is not an endorsement of any item. It is an attempt to sort what he uses by the strength of the evidence behind it, which is a more useful exercise than either reverence or mockery.

What is actually in the protocol right now?

The most peptide-dense single product is topical. Johnson’s Blueprint Peptide hair serum lists eight biomimetic peptides — EGF, Thymosin beta-4, SCF, hGH, VEGF, PDGF, Follistatin and Copper Tripeptide-1¹² — formulated for application to the scalp rather than injection. Separately, he consumes 20-30 g of collagen peptides daily alongside vitamin C,¹ a pairing chosen for collagen synthesis support.

Then there is the experimental tier. Johnson has reported, under an “in progress” label, stacking tirzepatide with CJC-1295 DAC¹⁴ on a personal theory that their opposite side effects might offset one another. Tirzepatide is an approved medicine in its own right;⁴ CJC-1295 DAC is a growth-hormone-releasing analogue used as a research reference compound. The “cancel-out” logic is the founder’s own hypothesis, not a documented pharmacological finding.

Johnson’s disclosed peptide-related items, sorted by current status and the strength of supporting evidence, mid-2025.

Which of these has evidence behind it?

At the credible end sits Copper Tripeptide-1, better known as GHK-Cu.² It has a genuine body of cosmetic and preclinical skin research,² and its inclusion in a topical scalp formulation is the least speculative thing on the list. It is worth being precise about what “real data” means here, though: much of that evidence is cosmetic and preclinical — cell-culture and animal models, plus formulation-level cosmetic use — rather than the controlled clinical endpoints a regulator would demand of a drug. The accompanying growth factors — EGF, Thymosin beta-4 (the peptide also catalogued as TB-500)³, VEGF, PDGF and the rest — carry preclinical skin and wound-related data, though delivering large peptides through intact scalp skin is itself an open question. Growth factors are sizeable molecules, and whether they cross the stratum corneum in a biologically meaningful amount from a leave-on serum is not something the ingredient list alone can settle. The collagen-plus-vitamin-C habit is mundane by comparison and the closest thing here to settled practice.

Tirzepatide is the only fully approved medicine in the set,⁴ regulated and indicated for its own purpose. But approval of a drug says nothing about the safety or rationale of pairing it with a research-grade secretagogue on a self-devised theory. The “offsetting side effects” premise is intuitive but unverified: it presumes that two compounds with opposing tendencies will net out cleanly in a single body, when interactions between agents acting on different pathways are rarely so tidy, and no controlled data exist for this particular pairing. That combination remains an n=1 experiment, and a positive personal report from it would still not be evidence of the mechanism Johnson proposes.

8 biomimetic peptides are combined in a single topical scalp serum — the densest peptide stack in the disclosed protocol.

What did he try and abandon — and why does that matter?

The instructive failures are the point. Johnson tried Cerebrolysin and said it felt like the best cognitive boost he had ever experienced — and then stopped it, because his formal biomarkers showed nothing.¹⁵ That is the moment most worth highlighting. The gap between a vivid subjective “best ever” and a flat objective readout is precisely where self-experimentation usually breaks down: the felt effect is real to the person feeling it, yet it is exactly the kind of signal — expectancy, novelty, placebo — that keeps weakly evidenced nootropics in circulation⁵ long after controlled trials would have retired them. Overriding that sensation with a null objective result, and acting on the null, is the empiricism the field routinely lacks.

The most valuable thing in Bryan Johnson’s protocol is not a peptide. It is the willingness to drop one that felt like it worked when the data said it did not.

The bioregulators followed a similar arc. Epithalon (Epitalon) and Thymulin were announced in 2024 and have since dropped off the protocol,¹⁶ consistent with their thin evidence base. BPC-157, frequently associated with Johnson in popular coverage,¹ sits in a different category again: he has experimented with it, but it is not part of his current disclosed protocol.

What should a careful reader take away — and what stays uncertain?

Several honest ambiguities survive any fair reading. The protocol is self-reported and evolving, so today’s snapshot may already be stale. “Felt nothing on biomarkers” is a verdict about Johnson’s specific panel, not a universal pharmacological conclusion — a different battery of measures, or a different person, might read differently. Topical delivery of large peptides through skin remains mechanistically unsettled, however plausible the individual ingredients. And the tirzepatide-CJC stack is a single person’s hypothesis being tested in real time, not a result. None of these caveats is hidden in the record; preserving them, rather than flattening them into a cleaner story, is the point of the exercise.

The compounds discussed here — GHK-Cu, Thymosin beta-4 (TB-500), tirzepatide, CJC-1295 DAC, Epitalon, Cerebrolysin and BPC-157²³⁴⁶ — are catalogued by Condor Research as characterised, research-use-only reference materials, not as the regulated or approved products a clinic would dispense. This article is a fact-check of one public figure’s evolving protocol, not medical advice and not a protocol for anyone to copy. Where an item is an approved medicine, that status belongs to the licensed drug and its indication — not to a research-grade analogue. Honesty about evidence, including where it runs out, is the standard we hold ourselves to.